Good scores do not always mean lower danger.
Boston, April 2026
A growing body of research is challenging a basic assumption behind Alzheimer’s screening: that the same cognitive tests capture early decline equally well in women and men. Recent findings suggest that some women may perform relatively well on standard screening tools even while underlying brain changes are already advancing, which means risk can be underestimated at the exact stage when earlier detection matters most. In practical terms, a reassuring test result may sometimes hide vulnerability rather than rule it out.
The issue is especially significant because many frontline assessments still rely heavily on memory and cognitive scores that were not designed around sex-specific differences in how decline can present. Women often show stronger verbal memory performance in the early phases, which can delay the moment when conventional tests begin to signal a problem. That does not mean the disease is absent. It means the usual instruments may not always register it with the same sensitivity.
This matters clinically because delayed recognition changes the entire care pathway. If a woman appears cognitively stronger on standard screening, physicians and families may be less likely to push for deeper evaluation in the early stages. The result can be a diagnostic lag, with monitoring, intervention, and long-term planning arriving later than they should. The concern is not that these tests are useless, but that they may be insufficient when interpreted without greater nuance.
The broader medical concern is even more serious because women represent a large share of Alzheimer’s cases, and some researchers believe biological and hormonal factors may shape vulnerability differently across the life course. That has intensified the call for screening models that do not rely on a one-size-fits-all logic. A test can be standardized and still miss important differences in how disease manifests across populations.
What emerges from this debate is a larger lesson about medical measurement. A patient can score well and still carry meaningful risk if the tool is not calibrated to how symptoms unfold in that person’s demographic profile. In Alzheimer’s screening, that may mean a woman’s apparently reassuring score is not always as reassuring as clinicians assume. The challenge now is to move toward assessment models that combine cognitive testing with biomarkers, imaging, and sex-aware interpretation.
What is at stake is not only diagnostic accuracy, but timing. In neurodegenerative disease, time is one of the most valuable clinical variables. If risk in women is being masked by the very tools meant to detect it, then the problem is not simply technical. It is structural. And correcting it could change who gets seen early enough for the diagnosis to matter.
Behind every fact, there is an intention. Behind every silence, a structure.